According to the companies, an objective response rate of 54.8% was observed with Daiichi Sankyo and Merck's ifinatamab deruxtecan at a 12 mg/kg dose in pretreated patients. This dose has been ...

BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--Results from an interim analysis of the dose-optimization part of the ongoing IDeate-Lung01 phase 2 trial showed ifinatamab deruxtecan (I-DXd ...

Daiichi Sankyo granted Merck exclusive, worldwide rights (excluding Japan) to co-develop and co-commercialize Daiichi's 3 antibody-drug conjugates (ADCs) including patritumab deruxtecan (HER3-DXd ...

The revenue for Datopotamab deruxtecan is expected to reach an annual total of $1.45 bn by 2037 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs ...

Enhertu (fam-trastuzumab deruxtecan-nxki) is a prescription drug that’s used to treat certain cancers, such as breast cancer. Enhertu can cause side effects that range from mild to serious.

Enhertu (fam-trastuzumab deruxtecan-nxki) is a prescription drug that’s used to treat certain types of cancer. Enhertu’s cost may depend on factors such as your dosage, whether you have health ...

KDA launches a campaign at Vikasa Soudha to teach Kannada to non-Kannadigas Reflecting on the contemporary urban scenario, Bilimale lamented, "The Kannada language is in crisis. Evidently, Kannada ...

Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone In a final analysis of ...

New changes to the UK's immigration laws, including substantial increases to visa fees and higher salary thresholds for applicants, are raising concern among cancer researchers and other stakeholders ...

Political parties in the UK have set out plans for improving cancer care in their manifestos published ahead of the country's general election on July 4, 2024.

Raludotatug deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase ...